🇺🇸 Biosynthetic Human Insulin Injection in United States

8 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Cerebral Infarction — 1 report (12.5%)
  2. Death — 1 report (12.5%)
  3. Gastrointestinal Haemorrhage — 1 report (12.5%)
  4. Hypoproteinaemia — 1 report (12.5%)
  5. Myelosuppression — 1 report (12.5%)
  6. Platelet Count Decreased — 1 report (12.5%)
  7. Septic Shock — 1 report (12.5%)
  8. Thrombocytopenia — 1 report (12.5%)

Source database →

Biosynthetic Human Insulin Injection in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Biosynthetic Human Insulin Injection approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Biosynthetic Human Insulin Injection in United States?

Servier (Tianjin) Pharmaceutical Co. LTD. is the originator. The local marketing authorisation holder may differ — check the official source linked above.